Company intelligence / Profile preview

Miikana Therapeutics

Fremont, California, United Statespitchbook.com ↗

Ownership: Private
Development stage: Phase 2

Overview

Miikana Therapeutics built an oncology-focused pipeline through both internal discovery and in‑licensing strategies. Its assets included small molecule drug candidates such as an aurora kinase inhibitor and an HDAC inhibitor. The company received a worldwide license for MKC‑1 from Hoffmann-La Roche. In December 2005, it was acquired by EntreMed, Inc., which integrated its pipeline into broader multi-mechanism oncology and inflammation drug development efforts. Clinical results for individual compounds are not detailed in public sources; most programs were preclinical or early-stage at the time of acquisition.

Therapeutic areas: OncologyImmunology
Modalities: Small moleculesHDAC inhibitorsaurora kinase inhibitors
Industry: Biotech

Drug pipeline

1 asset

ENMD-2076

Phase 2

Indications: Ovarian cancer, Cancer

Partnerships

Exclusive worldwide license with Hoffmann-La Roche for MKC–1 development/manufacturing/commercialization rights prior to acquisition by EntreMed.

Beyond the preview

Go deeper on Miikana Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Miikana Therapeutics.

Explore the full profile